Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Medtronic's Evolut FX TAVR valve, designed with 3 golden markers that improve alignment

Medtronic receives CE mark approval for Evolut FX TAVR system

The self-expanding valve, already approved by the FDA, was designed with three gold markers to boost implanter efficiency, an updated catheter tip and a more flexible delivery system.

The SavvyWire TAVR guidewire by OpSens / Haemonetics

Haemonetics to acquire medical device company known for its TAVR guidewires for $253M

Haemonetics expects the deal to increase its short- and long-term revenue. The all-cash transaction should close by January 2024.

AI artificial intelligence stethoscope doctor

AI model detects multiple heart issues in a single 10-second audio clip

The advanced algorithm achieved a sensitivity of 93% and specificity of 98%. It was trained to identify up to five different valvular diseases at the same time from a single audio clip.

The Pioneer TAVR system from KOKA Lifesciences

New TAVR system for pure aortic regurgitation used for first time, linked to ‘excellent’ short-term outcomes

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

healthcare value value-based care money dollar

Cardiologists, cardiac surgeons push insurance company to rethink billing policy

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons raised the issue, which is related to the billing of transcatheter heart procedures such as TAVR. 

Thumbnail

Stroke after TAVR: New research helps cardiologists detect early warning signs

Post-TAVR stroke is rare, but it can be fatal. A new study in Catheterization and Cardiovascular Interventions examined the issue in great detail, focusing on more than 2,700 patients treated over a two-year stretch. 

Death after TAVR: Heart failure, sudden cardiac arrest stand out as 2 leading causes

A majority of patient deaths within two years of TAVR can be linked to cardiovascular complications, according to new research published in JACC: Cardiovascular Interventions. Can follow-up care be improved to combat this trend? 

Video of Prof. Dr. Ralph Stephan von Bardeleben explaining the latest details from key tricuspid valve trials.

What new tricuspid valve data tell us about the future of patient care

What are the latest updates on treating tricuspid regurgitation? We spoke with a leading researcher at ESC Congress 2023 to find out. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup